Lincomycin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Lincomycin
- Lincomycin: From Pneumococcal/Staphylococcal/Streptococcal Infections to Polyclonal Hyperviscosity Syndrome
Lincomycin: From Pneumococcal/Staphylococcal/Streptococcal Infections to Polyclonal Hyperviscosity Syndrome
One-Sentence Summary
Lincomycin is a lincosamide antibiotic originally used to treat pneumococcal, staphylococcal and streptococcal infections. The TxGNN model predicts it may be effective for polyclonal hyperviscosity syndrome, but no clinical trials and no publications support this prediction, so it rests on a computational score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Pneumococcal infection, staphylococcal infection, streptococcal infection |
| Predicted New Indication | Polyclonal hyperviscosity syndrome |
| TxGNN Prediction Score | 99.14% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Lincomycin is generally known as a lincosamide antibiotic that inhibits bacterial protein synthesis at the 50S ribosomal subunit. Its efficacy against Gram-positive bacterial infections is established.
Polyclonal hyperviscosity syndrome is a blood and immunoglobulin-driven disorder, not a bacterial infection. No identifiable mechanistic link exists between a bacterial ribosome inhibitor and this condition. The high score (0.991) reflects proximity in the knowledge graph only and should not be read as evidence of benefit.
Other top-ranked predictions show the same pattern. Hyperamylasemia, congenital analbuminemia, blood group incompatibility, premalignant hematological disease, monoclonal gammopathy and congenital hematological disorders all lack a plausible mechanism and any supporting evidence. Only two predictions are biologically plausible because they are bacterial infections: septicemic plague (rank 8) and urinary tract infection (rank 10). Both are discussed below.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for polyclonal hyperviscosity syndrome.
For reference, the literature retrieved for other predicted indications is limited and does not demonstrate efficacy:
| Predicted Indication | PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|---|
| Urinary tract infection | 1433889 | 1992 | RCT (combination comparator) | Jpn J Antibiot | Imipenem/cilastatin vs aztreonam + lincomycin in 95 patients with severe infections and malignancy or haematological disease; does not isolate lincomycin's contribution |
| Urinary tract infection | 933394 | 1976 | Review | JACEP | Common childhood bacterial infections; lists lincomycin among suggested antibiotics |
| Septicemic plague | 1300928 | 1992 | In vitro survey | Antibiot Khimioter | Antibiotic sensitivity of plague strains; isolates were resistant to erythromycin and lincomycin |
| Septicemic plague | 7259143 | 1981 | In vitro survey | Antibiotiki | Antibiotic sensitivity of 91 plague strains from the Caucasus and Transcaucasia |
| Monoclonal gammopathy | 2714817 | 1989 | Laboratory study | Hybridoma | Antibiotics used to remove mycoplasma from mouse myeloma cell cultures; not clinical |
| Monoclonal gammopathy | 5299961 | 1967 | Clinical experience report | J Antibiot Ser B | General internal medicine experience with lincomycin; no efficacy shown for this condition |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN01866P | Lincomycin Injection 300 mg/ml (Shin Poong Pharmaceutical) | Injection | Not specified in the compiled data |
| SIN06683P | Lincomycin Injection 300 mg/ml (Yung Shin Pharmaceutical) | Injection | Not specified in the compiled data |
Safety Considerations
- Contraindication signals from the knowledge graph (not label text): liver failure, Clostridium difficile colitis, perinatal necrotizing enterocolitis, colitis, digestive system disease, intestinal disease.
- Drug Interactions: 21 interactions were recorded. Those rated moderate are balsalazide, picosulfuric acid, attapulgite, kaolin, erythromycin and ethinylestradiol. Others have an unrated severity, including clotrimazole, cimetidine, morphine, metformin, omeprazole, lactulose, triamcinolone, simvastatin, ranitidine, warfarin, lidocaine, cetirizine, montelukast and salmeterol.
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for polyclonal hyperviscosity syndrome has no mechanistic link, trials or literature, and rests only on a graph-based score. The more plausible antibacterial predictions (septicemic plague, urinary tract infection) are supported only by in vitro or non-specific data. Lincosamides are not established therapy for plague and lack activity against most common urinary pathogens.
To proceed, the following is needed:
- Package insert warnings and contraindications from HSA, which are currently missing and block safety screening
- Mechanism of action data from DrugBank
- A mechanistic hypothesis and preclinical or clinical evidence for the predicted indication
- If pursuing an antibacterial direction (such as urinary tract infection), lincomycin-specific susceptibility data and clinical comparisons that isolate its contribution
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.